Betoptic-S®
Betaxolol 0.25% · ophthalmic suspension
Antiglaucoma
Approved uses
Elevated IOP in chronic open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) BID
IOP starts falling within 30 minutes, peaks at 2 hours, and a single dose lasts 12 hours.
Contraindications
- Sinus bradycardia.
- Second or third degree atrioventricular block.
- Overt cardiac failure.
- Cardiogenic shock.
- Hypersensitivity to any component.
0.25% suspension (2.5 mg/mL betaxolol base), 10 mL, 15 mL
Cardioselective (beta-1-adrenergic) receptor inhibitor without significant membrane-stabilizing activity and devoid of intrinsic sympathomimetic action; the mechanism of ocular hypotensive action appears to be a reduction of aqueous production, as demonstrated by tonography and aqueous fluorophotometry. Onset can generally be noted within 30 minutes and maximum effect can usually be detected 2 hours after dosing; a single dose provides a 12-hour IOP reduction, and in some patients the response may require a few weeks to stabilize.
Warnings & Precautions
- Systemic absorption: This drug is absorbed systemically, and the same adverse reactions found with systemic beta-adrenergic receptor inhibitors may occur with topical administration. Severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and death due to cardiac failure, have been reported with topical beta-adrenergic receptor inhibitors.
- Cardiac failure: Minor effect on heart rate and blood pressure in clinical studies, but use caution with a history of cardiac failure or heart block and discontinue at the first signs of failure.
- Bronchospasm and pulmonary distress: Asthmatic attacks and pulmonary distress have been reported during betaxolol treatment; rechallenge of some such patients did not adversely affect pulmonary function test results, but adverse pulmonary effects in patients sensitive to beta-adrenergic receptor inhibitors cannot be ruled out. Caution with excessive restriction of pulmonary function.
- Diabetes mellitus: May mask the signs and symptoms of acute hypoglycemia; use with caution in patients subject to hypoglycemia and in diabetic patients (especially those with labile diabetes) receiving insulin or oral hypoglycemic agents.
- Thyrotoxicosis: May mask certain clinical signs (e.g., tachycardia) of hyperthyroidism; manage patients suspected of developing thyrotoxicosis carefully to avoid abrupt withdrawal, which might precipitate a thyroid storm.
- Muscle weakness: Beta-adrenergic receptor inhibitors have been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness).
- Surgical anesthesia: Withdrawal before major surgery is controversial. Beta-blockade impairs the heart's response to beta adrenergically mediated reflex stimuli, which may augment the risk of general anesthesia; protracted, severe hypotension during anesthesia and difficulty restarting and maintaining the heartbeat have been reported. Consider gradual withdrawal before elective surgery; if necessary, effects may be reversed by sufficient doses of adrenergic agonists.
- Atopy and anaphylaxis: Patients with atopy or prior severe anaphylaxis may be more reactive on repeat allergen challenge and unresponsive to usual epinephrine doses.
- Angle-closure glaucoma: Little or no effect on the pupil, so it should not be used alone when the immediate objective is reopening the angle.
- Vascular insufficiency: Use with caution in patients with vascular insufficiency because of potential effects on blood pressure and pulse; consider alternative therapy if reduced cerebral blood flow or Raynaud's phenomenon develops after starting treatment.
- Bacterial keratitis: May occur with use of multiple dose containers of topical ophthalmic products when these containers are inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Instruct patients on appropriate instillation techniques.
- Choroidal detachment: Reported with aqueous suppressant therapy after filtration procedures.
- Contact lens wear: The preservative benzalkonium chloride may be absorbed by soft contact lenses; remove lenses during instillation and reinsert after 15 minutes.
Common Side Effects
- Ocular: Transient ocular discomfort is the most frequent reaction; blurred vision, corneal punctate keratitis, foreign body sensation, photophobia, tearing, itching, dryness, erythema, inflammation, discharge, ocular pain, decreased visual acuity, and crusty lashes reported in small numbers of patients.
- Systemic: Bradycardia, heart block, and congestive failure; pulmonary distress with dyspnea, bronchospasm, thickened bronchial secretions, asthma, and respiratory failure; insomnia, dizziness, vertigo, headache, depression, lethargy, and increased signs of myasthenia gravis; hives, toxic epidermal necrolysis, hair loss, glossitis, and perverted taste or smell.
- Other betaxolol formulations: Allergic reactions, decreased corneal sensitivity, corneal punctate staining that may appear in dendritic formation, edema, and anisocoria.
Pregnancy: No adequate and well-controlled studies in pregnant women and only limited data with betaxolol eye drops; epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are given by the oral route. Use only if the potential benefit justifies the potential fetal risk.
Lactation: Beta-blockers are excreted in breast milk after oral dosing and have the potential to cause serious undesirable effects in a nursing infant; whether measurable levels reach milk after topical ocular use is unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breast-fed child.
Safety and IOP-lowering effect demonstrated in a 3-month, multicenter, double-masked, active-controlled pediatric trial.